Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Outlook 2026–2035 Driven by Key Growth Factors and Industry Projections
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Evolve From 2026 To 2030?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market has seen its size grow exponentially in recent years. This market is projected to expand from $13.29 billion in 2025 to $17.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 28.1%. The growth observed in the past can be attributed to several factors such as improved disease awareness among cardiologists, an increase in the diagnosis of rare cardiomyopathies, the availability of targeted pharmacological therapies, the expansion of specialty cardiac care centers, and progress in genetic screening technologies.
The market for transthyretin amyloid cardiomyopathy (attr-cm) treatments is projected to experience rapid expansion in the coming years. This market is anticipated to reach $45.09 billion by 2030, showing a compound annual growth rate (CAGR) of 27.6%. Factors contributing to this growth during the forecast period include the broader application of precision medicine, the increasing creation of next-generation gene-silencing treatments, higher investments in drug development for rare diseases, improved patient access to sophisticated cardiac diagnostic tools, and a sharpened emphasis on therapies that modify the disease. Key trends anticipated for the forecast period encompass a greater uptake of transthyretin stabilizer therapies, the increasing application of RNAi-based treatment methods, an enhanced focus on early detection and ongoing disease surveillance, the diversification of personalized treatment plans, and boosted funding for research into rare cardiac conditions.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
What Key Drivers Are Influencing The Growth Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The increasing incidence of chronic illnesses is anticipated to drive the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the future. These conditions are defined as persistent health issues that develop gradually and endure for at least a year, frequently necessitating ongoing medical attention. The growing occurrence of chronic ailments stems from factors including older demographics, inactive ways of life, poor dietary habits, escalating levels of obesity, and contact with environmental contaminants. Treatment for transthyretin amyloid cardiomyopathy works by stabilizing transthyretin, decreasing the accumulation of amyloid, enhancing cardiac performance, and easing symptoms to more effectively handle associated chronic conditions. For example, in April 2025, data from the Centers for Disease Control and Prevention (CDC), a federal agency in the US, indicated that in 2023, around 194 million U.S. adults, or 76.4%, reported experiencing at least one chronic condition. This prevalence stood at 59.5% for young adults, 78.4% for midlife adults, and 93.0% for older adults. Consequently, the increasing prevalence of chronic diseases is fueling the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Which Segment Areas Are Covered In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
What Major Market Trends Are Driving Changes In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Leading companies within the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are concentrating on creating novel therapies for ATTR-CM, including oral prescription drugs designed to target and stabilize transthyretin (TTR) proteins or decrease the accumulation of amyloid fibrils in the heart. These oral prescription medications are drugs prescribed by medical professionals, intended for consumption by mouth, commonly available as tablets, capsules, or liquid formulations. An example of this is the U.S. Food and Drug Administration’s approval in November 2024 of Attruby (acoramidis) for treating adults with transthyretin amyloid cardiomyopathy (ATTR-CM), developed by the US-based biotechnology firm, BridgeBio Pharma Inc. This medication works by stabilizing the TTR protein, thereby lowering the incidence of heart-related fatalities and hospital admissions. Studies have demonstrated its good tolerability and its quick effectiveness by addressing the fundamental cause of the condition.
Which Global Companies Are Actively Competing In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Major companies operating in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc
Read the full transthyretin amyloid cardiomyopathy (attr-cm) treatment market report here:
Which Region Is Expected To Register The Fastest Growth In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp
Browse Through More Reports Similar to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market 2026, By The Business Research Company
Hypertrophic Cardiomyopathy Treatment Global Market Report
Hypertrophic Cardiomyopathy Hcm Therapeutics Global Market Report
Cardiometabolic Diseases Global Market Report
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
